126 related articles for article (PubMed ID: 22542492)
21. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
22. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1302-7. PubMed ID: 18495311
[TBL] [Abstract][Full Text] [Related]
24. Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Tatara A; Shimizu S; Masui A; Tamura M; Minamimoto S; Mizuguchi Y; Ochiai M; Mizobe Y; Ohno Y
Pharmacol Biochem Behav; 2015 Nov; 138():14-9. PubMed ID: 26363311
[TBL] [Abstract][Full Text] [Related]
25. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
26. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake.
Shobo M; Kondo Y; Yamada H; Mihara T; Yamamoto N; Katsuoka M; Harada K; Ni K; Matsuoka N
J Pharmacol Exp Ther; 2010 Jun; 333(3):772-81. PubMed ID: 20223878
[TBL] [Abstract][Full Text] [Related]
27. Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice.
Nair V; Arjuman A; Dorababu P; Gopalakrishna HN; Chakradhar Rao U; Mohan L
Indian J Med Res; 2007 Nov; 126(5):480-4. PubMed ID: 18160755
[TBL] [Abstract][Full Text] [Related]
28. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Rasmussen K; Hsu MA; Noone S; Johnson BG; Thompson LK; Hemrick-Luecke SK
Schizophr Bull; 2007 Nov; 33(6):1291-7. PubMed ID: 17660489
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat.
Ionov ID; Severtsev NN
Pharmacol Biochem Behav; 2012 Dec; 103(2):295-8. PubMed ID: 23036801
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Wynchank D; Berk M
Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
[TBL] [Abstract][Full Text] [Related]
31. Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats.
Berendsen HH; Broekkamp CL; Pinder RM
Psychopharmacology (Berl); 1998 Feb; 135(3):284-9. PubMed ID: 9498732
[TBL] [Abstract][Full Text] [Related]
32. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.
Shimizu S; Tatara A; Imaki J; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):877-81. PubMed ID: 20398719
[TBL] [Abstract][Full Text] [Related]
33. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
Zhang Y; Xu H; He J; Yan B; Jiang W; Li X; Li XM
Neurosci Lett; 2007 Jun; 420(1):66-71. PubMed ID: 17466452
[TBL] [Abstract][Full Text] [Related]
34. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression.
Yoshimura R; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Katsuki A; Hayashi K; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):308-12. PubMed ID: 20005280
[TBL] [Abstract][Full Text] [Related]
35. Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats.
Shireen E; Haleem DJ
Pak J Pharm Sci; 2011 Jan; 24(1):7-12. PubMed ID: 21190911
[TBL] [Abstract][Full Text] [Related]
36. Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes.
González-Lugo OE; Ceballos-Huerta F; Jiménez-Capdeville ME; Arankowsky-Sandoval G; Góngora-Alfaro JL
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1465-71. PubMed ID: 20713114
[TBL] [Abstract][Full Text] [Related]
37. [Effects of chronic fluoxetine treatment on catalepsy and immune response in mice genetically predisposed to freezing reaction: the role of 5-HT1A and 5-HT2A receptors and tph2 and SERT genes].
Tikhonova MA; Al'perina EL; Tolstikova TG; Bazovkina DV; Di VIu; Idova GV; Kulikov AV; Popova NK
Zh Vyssh Nerv Deiat Im I P Pavlova; 2009; 59(2):237-44. PubMed ID: 19445393
[TBL] [Abstract][Full Text] [Related]
38. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of atypical antipsychotics in mood disorders.
Yatham LN
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S9-14. PubMed ID: 12832944
[TBL] [Abstract][Full Text] [Related]
40. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability.
Hoffman DC; Donovan H
Psychopharmacology (Berl); 1995 Jul; 120(2):128-33. PubMed ID: 7480543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
